Press Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor Mar 17 • 4 min read Newscope Capital Corporation, through its wholly-owned subsidiary, PharmaTher Inc., announced the appointment of Dr. Maurizio Fava, MD, as a scientific and clinical advisor for PharmaTher’s clinical research initiatives with KETABET™
Press PharmaTher Announces Research Collaboration for Microneedle Delivery of Psychedelic Pharmaceuticals Feb 23 • 4 min read PharmaTher Inc. announced that they have entered into a sponsored research agreement with the Terasaki Institute to develop a novel microneedle patch that aims to deliver psychedelic pharmaceuticals.
Press PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine Feb 1 • 5 min read Newscope Capital Corporation, who through its wholly-owned subsidiary, PharmaTher Inc. is pleased to announce that PharmaTher has entered into an exclusive worldwide patent for the development of a patented hydrogel-forming microneedle delivery technology with ketamine.
Press PharmaTher Signs License Agreement for Patented Ketamine Treatment Jan 22 • 3 min read PharmaTher has entered an agreement with the National Health Research Institutes of Taiwan to develop and commercialize a patented formulation of FDA-approved ketamine and betaine combination called KETABET.
Press PharmaTher Approved to Trade on the OTCQB Venture Market Jan 13 • 2 min read Newscope Capital Corporation, who through its wholly-owned subsidiary, PharmaTher Inc., announced that its common shares have been approved for trading on the OTCQB® Venture Market effective today.